Literature DB >> 10567193

11beta-hydroxysteroid dehydrogenase and corticosteroid action in lyon hypertensive rats.

S A Lloyd-MacGilp1, S M Nelson, M Florin, M Lo, J McKinnell, J Sassard, C J Kenyon.   

Abstract

Adrenocorticosteroid activity in Lyon hypertensive (LH) and low blood pressure (LL) rat strains differ in several respects. Abnormal activity of 11beta-hydroxysteroid dehydrogenase enzymes (11beta-HSD1 and 11beta-HSD2), which interconvert corticosterone and inactive 11-dehydrocorticosterone, might contribute to the LH phenotype by regulating corticosteroid hormone access to receptors. 11beta-HSD2 (expressed in kidney but not liver) prevents endogenous glucocorticoids from binding to mineralocorticoid receptors. 11beta-HSD1 (expressed in liver and kidney) favors active glucocorticoid formation from 11-dehydrocorticosterone. 11beta-HSD properties in LH and LL have been compared by several approaches: (1) 11betaHSD activities have been measured in vitro as corticosterone dehydrogenation and in vivo as interconversion of injected cortisol and cortisone; (2) the effects of cortisol and cortisone on urine electrolytes and volume have been measured; and (3) 11beta-HSD mRNA expression has been measured by in situ hybridization. 11beta-HSD2 enzyme activities in LH and LL rats were similar and urinary cortisone:cortisol ratios were not different after cortisol injection. Cortisol caused a natriuresis and kaliuresis in both strains, with a slightly reduced response in LH rats. Renal 11beta-HSD2 mRNA expression was slightly lower in LH rats. 11beta-HSD1 was less active in LH than LL rats: enzyme activities were lower in tissue extracts; urinary cortisone:cortisol was lower in LL rats after cortisone injections; cortisone increased urine volume in LL but not LH rats; and mRNA levels tended to be lower in LH tissues. We conclude that 11beta-HSD1 is impaired in LH rats. The LH phenotype of heavier adrenals, raised corticosterone, and reduced thymus weight is similar to that described for 11beta-HSD1 knockout mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567193     DOI: 10.1161/01.hyp.34.5.1123

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.

Authors:  Pablo Stiefel; José S García-Morillo; Luis Jimenez; Encarnación Pamies; María Luisa Miranda; Joaquín Carneado; José Villar; Alfonso Leal-Cerro
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

2.  TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.

Authors:  Chengpeng Yu; Dean Rao; He Zhu; Qiumeng Liu; Wenjie Huang; Long Zhang; Huifang Liang; Jia Song; Zeyang Ding
Journal:  Biomed Res Int       Date:  2021-08-13       Impact factor: 3.411

3.  Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance.

Authors:  Javad Habibi; Dongqing Chen; Jack L Hulse; Adam Whaley-Connell; James R Sowers; Guanghong Jia
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-02-02       Impact factor: 3.619

4.  The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.

Authors:  Minghan Wang
Journal:  Nutr Metab (Lond)       Date:  2005-02-02       Impact factor: 4.169

5.  Altered Regulation of Type II 11β-hydroxysteroid Dehydrogenase in the Kidney of Rats with Experimental Hypertension.

Authors:  Seong Su Kang; Soo Wan Kim; Jongun Lee
Journal:  Electrolyte Blood Press       Date:  2007-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.